focus -WSS

focus

author：comprehensive 2025-09-06 02:04:36 - browse：36

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

LONDON — A U.K. government agency on Tuesday said that it won’t recommend Eli Lilly’s Mounjaro — part of a new class of medications that help patients lose weight — for people with type 2 diabetes without additional evidence.

Mounjaro, also known as tirzepatide, has U.S. approval for type 2 diabetes and is expected to win the regulatory green light for obesity later this year. It is one of several medications, along with Wegovy and Ozempic from Novo Nordisk, that have shown dramatic weight loss results, creating a surge in demand and blockbuster sales expectations.

But in draft guidance, the U.K.’s National Institute for Health and Care Excellence, which assesses the cost-effectiveness of medications, said it had asked Lilly for more data “to address the uncertainties in the clinical evidence, when compared to all relevant alternative treatments.” NICE recommendations are used by the National Health Service to determine whether to provide certain medications.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： DIEP, the 'gold standard' of breast reconstruction, is under threat
Next article： IVF doctors demand details after CooperSurgical lawsuit

Wikipedia

WSS

Medicare drug price negotiation’s day in court

Families look for replacement for GSK asthma drug Flovent

General Catalyst, Summa Health deal will turn on physician buy

Cybersecurity threat forces Lurie Children's to take systems offline

Time to name cancers by genetics, not organ of origin, expert says

The real point of Kenneth Smith’s execution by nitrogen gas

knowledge

focus

focus

The high cost of giving birth even with insurance

A new approach to psychiatric drug development

Medical records are filled with copy

For AI in health care standards, federal regulators join with industry group

Continuity nursing helped my family in our darkest PICU moments

Families look for replacement for GSK asthma drug Flovent

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Biden administration opens offers in Medicare drug price negotiations

How to save PrEP access — and even expand it

First over

leisure time

FDA drug safety: Singulair case shows systemic surveillance flaws

$1 billion proposal to grow Boston, Massachusetts biotech

Medicare drug price negotiation hearing pits pharma v Biden admin

Covid misinformation case heads to Supreme Court

Congressmen charge Covid hearing ‘could have been an email’

$1 billion proposal to grow Boston, Massachusetts biotech

Wikipedia

knowledge

Wikipedia

hotspot